APO Research
Talk to an analyst

APO RESEARCH · REPORT

Adalimumab

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Adalimumab Market Outlook and Growth Opportunities 2026

22 December 2025196 pages

Choose your research edition.

Industry ResearchAdalimumab Industry Research Report 2026115 pages · $2,950 USDIndustry Growth & TrendsGlobal Adalimumab Industry Growth and Trends Forecast to 203295 pages · $3,450 USDMarket StructureGlobal Adalimumab Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032181 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Adalimumab Market Outlook and Growth Opportunities 2026196 pages · $4,250 USDMarket Analysis & ForecastGlobal Adalimumab Market Analysis and Forecast 2026-2032193 pages · $4,950 USD

Market perspective

The global Adalimumab market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Adalimumab is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Adalimumab is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Adalimumab is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Adalimumab market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Adalimumab market include Aark Pharmaceuticals, Amgevita, Biogen, Boehringer Ingelheim, Delphis Pharma, AbbVie, Amgen, Mylan and Sandoz, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Adalimumab market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Adalimumab and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Adalimumab sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Adalimumab market size, projected growth trends, production technologies, key applications, and end-use industries.

Adalimumab Segment by Company

Aark Pharmaceuticals

Amgevita

Biogen

Boehringer Ingelheim

Delphis Pharma

AbbVie

Amgen

Mylan

Sandoz

Adalimumab Segment by Type

Adalimumab

Adalimumab Biosimilar

Adalimumab Segment by Application

Adults

Children

Adalimumab Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Adalimumab status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Adalimumab market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Adalimumab significant trends, drivers, influence factors in global and regions.

6. To analyze Adalimumab competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Adalimumab market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Adalimumab and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Adalimumab.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Adalimumab market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Adalimumab industry.

Chapter 3: Detailed analysis of Adalimumab manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Adalimumab in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Adalimumab in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Adalimumab Industry Trends Table 2. Adalimumab Industry Drivers Table 3. Adalimumab Industry Opportunities and Challenges Table 4. Adalimumab Industry Restraints Table 5. Global Adalimumab Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Adalimumab Revenue Share by Company (2021-2026) Table 7. Global Adalimumab Sales Volume by Company (k units) & (2021-2026) Table 8. Global Adalimumab Sales Volume Share by Company (2021-2026) Table 9. Global Adalimumab Average Price (US$/unit) of Company (2021-2026) Table 10. Global Adalimumab Company Ranking, (2024-2026) & (USD Million) Table 11. Global Adalimumab Key Company Manufacturing Base & Headquarters Table 12. Global Adalimumab Company, Product Type & Application Table 13. Global Adalimumab Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Adalimumab by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Adalimumab Table 18. Significant Companies of Adalimumab Biosimilar Table 19. Global Adalimumab Sales Volume by Type 2021 VS 2025 VS 2032 (k units) Table 20. Global Adalimumab Sales Volume by Type (2021-2026) & (k units) Table 21. Global Adalimumab Sales Volume by Type (2027-2032) & (k units) Table 22. Global Adalimumab Sales Volume Share by Type (2021-2026) Table 23. Global Adalimumab Sales Volume Share by Type (2027-2032) Table 24. Global Adalimumab Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global Adalimumab Sales Value by Type (2021-2026) & (US$ Million) Table 26. Global Adalimumab Sales Value by Type (2027-2032) & (US$ Million) Table 27. Global Adalimumab Sales Value Share by Type (2021-2026) Table 28. Global Adalimumab Sales Value Share by Type (2027-2032) Table 29. Significant Companies of Adults Table 30. Significant Companies of Children Table 31. Global Adalimumab Sales Volume by Application 2021 VS 2025 VS 2032 (k units) Table 32. Global Adalimumab Sales Volume by Application (2021-2026) & (k units) Table 33. Global Adalimumab Sales Volume by Application (2027-2032) & (k units) Table 34. Global Adalimumab Sales Volume Share by Application (2021-2026) Table 35. Global Adalimumab Sales Volume Share by Application (2027-2032) Table 36. Global Adalimumab Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 37. Global Adalimumab Sales Value by Application (2021-2026) & (US$ Million) Table 38. Global Adalimumab Sales Value by Application (2027-2032) & (US$ Million) Table 39. Global Adalimumab Sales Value Share by Application (2021-2026) Table 40. Global Adalimumab Sales Value Share by Application (2027-2032) Table 41. Global Adalimumab Sales by Region: 2021 VS 2025 VS 2032 (k units) Table 42. Global Adalimumab Sales by Region (2021-2026) & (k units) Table 43. Global Adalimumab Sales Market Share by Region (2021-2026) Table 44. Global Adalimumab Sales by Region (2027-2032) & (k units) Table 45. Global Adalimumab Sales Market Share by Region (2027-2032) Table 46. Global Adalimumab Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 47. Global Adalimumab Sales Value by Region (2021-2026) & (US$ Million) Table 48. Global Adalimumab Sales Value Share by Region (2021-2026) Table 49. Global Adalimumab Sales Value by Region (2027-2032) & (US$ Million) Table 50. Global Adalimumab Sales Value Share by Region (2027-2032) Table 51. Global Adalimumab Market Average Price (US$/unit) by Region (2021-2026) Table 52. Global Adalimumab Market Average Price (US$/unit) by Region (2027-2032) Table 53. Global Adalimumab Sales by Country: 2021 VS 2025 VS 2032 (k units) Table 54. Global Adalimumab Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 55. Global Adalimumab Sales by Country (2021-2026) & (k units) Table 56. Global Adalimumab Sales Market Share by Country (2021-2026) Table 57. Global Adalimumab Sales by Country (2027-2032) & (k units) Table 58. Global Adalimumab Sales Market Share by Country (2027-2032) Table 59. Global Adalimumab Sales Value by Country (2021-2026) & (US$ Million) Table 60. Global Adalimumab Sales Value Market Share by Country (2021-2026) Table 61. Global Adalimumab Sales Value by Country (2027-2032) & (US$ Million) Table 62. Global Adalimumab Sales Value Market Share by Country (2027-2032) Table 63. Aark Pharmaceuticals Company Information Table 64. Aark Pharmaceuticals Business Overview Table 65. Aark Pharmaceuticals Adalimumab Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 66. Aark Pharmaceuticals Adalimumab Product Portfolio Table 67. Aark Pharmaceuticals Recent Development Table 68. Amgevita Company Information Table 69. Amgevita Business Overview Table 70. Amgevita Adalimumab Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 71. Amgevita Adalimumab Product Portfolio Table 72. Amgevita Recent Development Table 73. Biogen Company Information Table 74. Biogen Business Overview Table 75. Biogen Adalimumab Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 76. Biogen Adalimumab Product Portfolio Table 77. Biogen Recent Development Table 78. Boehringer Ingelheim Company Information Table 79. Boehringer Ingelheim Business Overview Table 80. Boehringer Ingelheim Adalimumab Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 81. Boehringer Ingelheim Adalimumab Product Portfolio Table 82. Boehringer Ingelheim Recent Development Table 83. Delphis Pharma Company Information Table 84. Delphis Pharma Business Overview Table 85. Delphis Pharma Adalimumab Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 86. Delphis Pharma Adalimumab Product Portfolio Table 87. Delphis Pharma Recent Development Table 88. AbbVie Company Information Table 89. AbbVie Business Overview Table 90. AbbVie Adalimumab Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 91. AbbVie Adalimumab Product Portfolio Table 92. AbbVie Recent Development Table 93. Amgen Company Information Table 94. Amgen Business Overview Table 95. Amgen Adalimumab Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 96. Amgen Adalimumab Product Portfolio Table 97. Amgen Recent Development Table 98. Mylan Company Information Table 99. Mylan Business Overview Table 100. Mylan Adalimumab Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 101. Mylan Adalimumab Product Portfolio Table 102. Mylan Recent Development Table 103. Sandoz Company Information Table 104. Sandoz Business Overview Table 105. Sandoz Adalimumab Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 106. Sandoz Adalimumab Product Portfolio Table 107. Sandoz Recent Development Table 108. Key Raw Materials Table 109. Raw Materials Key Suppliers Table 110. Adalimumab Distributors List Table 111. Adalimumab Customers List Table 112. Research Programs/Design for This Report Table 113. Authors List of This Report Table 114. Secondary Sources Table 115. Primary Sources List of Figures Figure 1. Adalimumab Product Image Figure 2. Global Adalimumab Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Adalimumab Sales Value (2021-2032) & (US$ Million) Figure 4. Global Adalimumab Sales (2021-2032) & (k units) Figure 5. Global Adalimumab Sales Average Price (US$/unit) & (2021-2032) Figure 6. Global Adalimumab Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Adalimumab Image Figure 10. Adalimumab Biosimilar Image Figure 11. Global Adalimumab Sales Volume by Type (2021 VS 2025 VS 2032) & (k units) Figure 12. Global Adalimumab Sales Volume Share 2021 VS 2025 VS 2032 Figure 13. Global Adalimumab Sales Volume Share by Type (2021-2032) Figure 14. Global Adalimumab Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 15. Global Adalimumab Sales Value Share 2021 VS 2025 VS 2032 Figure 16. Global Adalimumab Sales Value Share by Type (2021-2032) Figure 17. Adults Image Figure 18. Children Image Figure 19. Global Adalimumab Sales Volume by Application (2021 VS 2025 VS 2032) & (k units) Figure 20. Global Adalimumab Sales Volume Share 2021 VS 2025 VS 2032 Figure 21. Global Adalimumab Sales Volume Share by Application (2021-2032) Figure 22. Global Adalimumab Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 23. Global Adalimumab Sales Value Share 2021 VS 2025 VS 2032 Figure 24. Global Adalimumab Sales Value Share by Application (2021-2032) Figure 25. Global Adalimumab Sales by Region: 2021 VS 2025 VS 2032 (k units) Figure 26. Global Adalimumab Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 27. Global Adalimumab Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 28. Global Adalimumab Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 29. North America Adalimumab Sales Value (2021-2032) & (US$ Million) Figure 30. North America Adalimumab Sales Value Share by Country (%), 2025 VS 2032 Figure 31. Europe Adalimumab Sales Value (2021-2032) & (US$ Million) Figure 32. Europe Adalimumab Sales Value Share by Country (%), 2025 VS 2032 Figure 33. Asia-Pacific Adalimumab Sales Value (2021-2032) & (US$ Million) Figure 34. Asia-Pacific Adalimumab Sales Value Share by Country (%), 2025 VS 2032 Figure 35. South America Adalimumab Sales Value (2021-2032) & (US$ Million) Figure 36. South America Adalimumab Sales Value Share by Country (%), 2025 VS 2032 Figure 37. Middle East & Africa Adalimumab Sales Value (2021-2032) & (US$ Million) Figure 38. Middle East & Africa Adalimumab Sales Value Share by Country (%), 2025 VS 2032 Figure 39. USA Adalimumab Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 40. USA Adalimumab Sales Value Share by Type, 2025 VS 2032 & (%) Figure 41. USA Adalimumab Sales Value Share by Application, 2025 VS 2032 & (%) Figure 42. Canada Adalimumab Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 43. Canada Adalimumab Sales Value Share by Type, 2025 VS 2032 & (%) Figure 44. Canada Adalimumab Sales Value Share by Application, 2025 VS 2032 & (%) Figure 45. Mexico Adalimumab Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. Mexico Adalimumab Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. Mexico Adalimumab Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. Germany Adalimumab Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. Germany Adalimumab Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. Germany Adalimumab Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. France Adalimumab Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. France Adalimumab Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. France Adalimumab Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. U.K. Adalimumab Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. U.K. Adalimumab Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. U.K. Adalimumab Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. Italy Adalimumab Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. Italy Adalimumab Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. Italy Adalimumab Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. Spain Adalimumab Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. Spain Adalimumab Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. Spain Adalimumab Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. Russia Adalimumab Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. Russia Adalimumab Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. Russia Adalimumab Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. Netherlands Adalimumab Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. Netherlands Adalimumab Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. Netherlands Adalimumab Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. Nordic Countries Adalimumab Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. Nordic Countries Adalimumab Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. Nordic Countries Adalimumab Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. China Adalimumab Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. China Adalimumab Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. China Adalimumab Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. Japan Adalimumab Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. Japan Adalimumab Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. Japan Adalimumab Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. South Korea Adalimumab Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. South Korea Adalimumab Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. South Korea Adalimumab Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. India Adalimumab Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. India Adalimumab Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. India Adalimumab Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. Australia Adalimumab Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. Australia Adalimumab Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. Australia Adalimumab Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. Southeast Asia Adalimumab Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. Southeast Asia Adalimumab Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. Southeast Asia Adalimumab Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Brazil Adalimumab Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Brazil Adalimumab Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Brazil Adalimumab Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Argentina Adalimumab Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Argentina Adalimumab Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Argentina Adalimumab Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Chile Adalimumab Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Chile Adalimumab Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Chile Adalimumab Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Colombia Adalimumab Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Colombia Adalimumab Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Colombia Adalimumab Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. Peru Adalimumab Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. Peru Adalimumab Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. Peru Adalimumab Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. Saudi Arabia Adalimumab Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. Saudi Arabia Adalimumab Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. Saudi Arabia Adalimumab Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Israel Adalimumab Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Israel Arabia Adalimumab Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Israel Arabia Adalimumab Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. UAE Adalimumab Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. UAE Adalimumab Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. UAE Adalimumab Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. Turkey Adalimumab Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 115. Turkey Adalimumab Sales Value Share by Type, 2025 VS 2032 & (%) Figure 116. Turkey Adalimumab Sales Value Share by Application, 2025 VS 2032 & (%) Figure 117. Iran Adalimumab Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 118. Iran Adalimumab Sales Value Share by Type, 2025 VS 2032 & (%) Figure 119. Iran Adalimumab Sales Value Share by Application, 2025 VS 2032 & (%) Figure 120. Egypt Adalimumab Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 121. Egypt Adalimumab Sales Value Share by Type, 2025 VS 2032 & (%) Figure 122. Egypt Adalimumab Sales Value Share by Application, 2025 VS 2032 & (%) Figure 123. Adalimumab Value Chain Figure 124. Manufacturing Cost Structure Figure 125. Adalimumab Sales Mode & Process Figure 126. Direct Comparison with Distribution Share Figure 127. Distributors Profiles Figure 128. Years Considered Figure 129. Research Process Figure 130. Key Executives Interviewed

Scope & coverage.

Types
  • Adalimumab
  • Adalimumab Biosimilar
Applications
  • Adults
  • Children
Companies covered
  • Aark Pharmaceuticals
  • Amgevita
  • Biogen
  • Boehringer Ingelheim
  • Delphis Pharma
  • AbbVie
  • Amgen
  • Mylan
  • Sandoz

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Adalimumab Sales Value (2021-2032)
  4. 1.2.2 Global Adalimumab Sales Volume (2021-2032)
  5. 1.2.3 Global Adalimumab Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Adalimumab Market Dynamics
  1. 2.1 Adalimumab Industry Trends
  2. 2.2 Adalimumab Industry Drivers
  3. 2.3 Adalimumab Industry Opportunities and Challenges
  4. 2.4 Adalimumab Industry Restraints
3 Adalimumab Market by Company
  1. 3.1 Global Adalimumab Company Revenue Ranking in 2025
  2. 3.2 Global Adalimumab Revenue by Company (2021-2026)
  3. 3.3 Global Adalimumab Sales Volume by Company (2021-2026)
  4. 3.4 Global Adalimumab Average Price by Company (2021-2026)
  5. 3.5 Global Adalimumab Company Ranking (2024-2026)
  6. 3.6 Global Adalimumab Company Manufacturing Base and Headquarters
  7. 3.7 Global Adalimumab Company Product Type and Application
  8. 3.8 Global Adalimumab Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Adalimumab Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Adalimumab Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Adalimumab Market by Type
  1. 4.1 Adalimumab Type Introduction
  2. 4.1.1 Adalimumab
  3. 4.1.2 Adalimumab Biosimilar
  4. 4.2 Global Adalimumab Sales Volume by Type
  5. 4.2.1 Global Adalimumab Sales Volume by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Adalimumab Sales Volume by Type (2021-2032)
  7. 4.2.3 Global Adalimumab Sales Volume Share by Type (2021-2032)
  8. 4.3 Global Adalimumab Sales Value by Type
  9. 4.3.1 Global Adalimumab Sales Value by Type (2021 VS 2025 VS 2032)
  10. 4.3.2 Global Adalimumab Sales Value by Type (2021-2032)
  11. 4.3.3 Global Adalimumab Sales Value Share by Type (2021-2032)
5 Adalimumab Market by Application
  1. 5.1 Adalimumab Application Introduction
  2. 5.1.1 Adults
  3. 5.1.2 Children
  4. 5.2 Global Adalimumab Sales Volume by Application
  5. 5.2.1 Global Adalimumab Sales Volume by Application (2021 VS 2025 VS 2032)
  6. 5.2.2 Global Adalimumab Sales Volume by Application (2021-2032)
  7. 5.2.3 Global Adalimumab Sales Volume Share by Application (2021-2032)
  8. 5.3 Global Adalimumab Sales Value by Application
  9. 5.3.1 Global Adalimumab Sales Value by Application (2021 VS 2025 VS 2032)
  10. 5.3.2 Global Adalimumab Sales Value by Application (2021-2032)
  11. 5.3.3 Global Adalimumab Sales Value Share by Application (2021-2032)
6 Adalimumab Regional Sales and Value Analysis
  1. 6.1 Global Adalimumab Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Adalimumab Sales by Region (2021-2032)
  3. 6.2.1 Global Adalimumab Sales by Region: 2021-2026
  4. 6.2.2 Global Adalimumab Sales by Region (2027-2032)
  5. 6.3 Global Adalimumab Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Adalimumab Sales Value by Region (2021-2032)
  7. 6.4.1 Global Adalimumab Sales Value by Region: 2021-2026
  8. 6.4.2 Global Adalimumab Sales Value by Region (2027-2032)
  9. 6.5 Global Adalimumab Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Adalimumab Sales Value (2021-2032)
  12. 6.6.2 North America Adalimumab Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Adalimumab Sales Value (2021-2032)
  15. 6.7.2 Europe Adalimumab Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Adalimumab Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Adalimumab Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Adalimumab Sales Value (2021-2032)
  21. 6.9.2 South America Adalimumab Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Adalimumab Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Adalimumab Sales Value Share by Country, 2025 VS 2032
7 Adalimumab Country-level Sales and Value Analysis
  1. 7.1 Global Adalimumab Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Adalimumab Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Adalimumab Sales by Country (2021-2032)
  4. 7.3.1 Global Adalimumab Sales by Country (2021-2026)
  5. 7.3.2 Global Adalimumab Sales by Country (2027-2032)
  6. 7.4 Global Adalimumab Sales Value by Country (2021-2032)
  7. 7.4.1 Global Adalimumab Sales Value by Country (2021-2026)
  8. 7.4.2 Global Adalimumab Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Adalimumab Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Adalimumab Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Adalimumab Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Adalimumab Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Adalimumab Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Adalimumab Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Adalimumab Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Adalimumab Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Adalimumab Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Adalimumab Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Adalimumab Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Adalimumab Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Adalimumab Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Adalimumab Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Adalimumab Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Adalimumab Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Adalimumab Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Adalimumab Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Adalimumab Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Adalimumab Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Adalimumab Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Adalimumab Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Adalimumab Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Adalimumab Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Adalimumab Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Adalimumab Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Adalimumab Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Adalimumab Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Adalimumab Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Adalimumab Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Adalimumab Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Adalimumab Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Adalimumab Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Adalimumab Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Adalimumab Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Adalimumab Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Adalimumab Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Adalimumab Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Adalimumab Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Adalimumab Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Adalimumab Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Adalimumab Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Adalimumab Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Adalimumab Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Adalimumab Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Adalimumab Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Adalimumab Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Adalimumab Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Adalimumab Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Adalimumab Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Adalimumab Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Adalimumab Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Adalimumab Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Adalimumab Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Adalimumab Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Adalimumab Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Adalimumab Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Adalimumab Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Adalimumab Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Adalimumab Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Adalimumab Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Adalimumab Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Adalimumab Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Adalimumab Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Adalimumab Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Adalimumab Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Adalimumab Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Adalimumab Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Adalimumab Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Adalimumab Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Adalimumab Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Adalimumab Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Adalimumab Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Adalimumab Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Adalimumab Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Adalimumab Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Adalimumab Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Adalimumab Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Adalimumab Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Adalimumab Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Adalimumab Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Adalimumab Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Adalimumab Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Adalimumab Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Aark Pharmaceuticals
  2. 8.1.1 Aark Pharmaceuticals Company Information
  3. 8.1.2 Aark Pharmaceuticals Business Overview
  4. 8.1.3 Aark Pharmaceuticals Adalimumab Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Aark Pharmaceuticals Adalimumab Product Portfolio
  6. 8.1.5 Aark Pharmaceuticals Recent Developments
  7. 8.2 Amgevita
  8. 8.2.1 Amgevita Company Information
  9. 8.2.2 Amgevita Business Overview
  10. 8.2.3 Amgevita Adalimumab Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Amgevita Adalimumab Product Portfolio
  12. 8.2.5 Amgevita Recent Developments
  13. 8.3 Biogen
  14. 8.3.1 Biogen Company Information
  15. 8.3.2 Biogen Business Overview
  16. 8.3.3 Biogen Adalimumab Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Biogen Adalimumab Product Portfolio
  18. 8.3.5 Biogen Recent Developments
  19. 8.4 Boehringer Ingelheim
  20. 8.4.1 Boehringer Ingelheim Company Information
  21. 8.4.2 Boehringer Ingelheim Business Overview
  22. 8.4.3 Boehringer Ingelheim Adalimumab Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Boehringer Ingelheim Adalimumab Product Portfolio
  24. 8.4.5 Boehringer Ingelheim Recent Developments
  25. 8.5 Delphis Pharma
  26. 8.5.1 Delphis Pharma Company Information
  27. 8.5.2 Delphis Pharma Business Overview
  28. 8.5.3 Delphis Pharma Adalimumab Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Delphis Pharma Adalimumab Product Portfolio
  30. 8.5.5 Delphis Pharma Recent Developments
  31. 8.6 AbbVie
  32. 8.6.1 AbbVie Company Information
  33. 8.6.2 AbbVie Business Overview
  34. 8.6.3 AbbVie Adalimumab Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 AbbVie Adalimumab Product Portfolio
  36. 8.6.5 AbbVie Recent Developments
  37. 8.7 Amgen
  38. 8.7.1 Amgen Company Information
  39. 8.7.2 Amgen Business Overview
  40. 8.7.3 Amgen Adalimumab Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 Amgen Adalimumab Product Portfolio
  42. 8.7.5 Amgen Recent Developments
  43. 8.8 Mylan
  44. 8.8.1 Mylan Company Information
  45. 8.8.2 Mylan Business Overview
  46. 8.8.3 Mylan Adalimumab Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 Mylan Adalimumab Product Portfolio
  48. 8.8.5 Mylan Recent Developments
  49. 8.9 Sandoz
  50. 8.9.1 Sandoz Company Information
  51. 8.9.2 Sandoz Business Overview
  52. 8.9.3 Sandoz Adalimumab Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 Sandoz Adalimumab Product Portfolio
  54. 8.9.5 Sandoz Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Adalimumab Value Chain Analysis
  2. 9.1.1 Adalimumab Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Adalimumab Sales Mode & Process
  6. 9.2 Adalimumab Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Adalimumab Distributors
  9. 9.2.3 Adalimumab Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst